Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Amneal Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 4/4

Amneal Pharmaceuticals' CEO'su Chirag Patel, Jan2005 tarihinde atandı, in görev süresi 19.75 yıldır. in toplam yıllık tazminatı $ 2.37M olup, şirket hissesi ve opsiyonları dahil olmak üzere 31.6% maaş ve 68.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 7.04% ine doğrudan sahiptir ve bu hisseler $ 181.23M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.3 yıl ve 6.4 yıldır.

Anahtar bilgiler

Chirag Patel

İcra Kurulu Başkanı

US$2.4m

Toplam tazminat

CEO maaş yüzdesi	31.6%
CEO görev süresi	19.8yrs
CEO sahipliği	7.0%
Yönetim ortalama görev süresi	5.3yrs
Yönetim Kurulu ortalama görev süresi	6.4yrs

Son yönetim güncellemeleri

Recent updates

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 10

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Apr 15

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Mar 19

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 28

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Apr 18

Amneal Pharmaceuticals: Risk Still Persists

Jan 23

Amneal Pharma reaffirms 2022 guidance

Jan 10

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Jan 04

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Dec 20

Amneal Pharmaceuticals large shareholder TPG cuts stake

Dec 14

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Nov 11

Amneal Pharmaceuticals Q3 2022 Earnings Preview

Nov 03

Amneal Pharmaceuticals: A Small 'Thumbs Up'

Oct 28

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Sep 01

Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment

Aug 31

Amneal Pharmaceuticals Q2 2022 Earnings Preview

Aug 04

CEO Tazminat Analizi

Chirag Patel'un ücretlendirmesi Amneal Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$175m
Mar 31 2024	n/a	n/a	-US$169m
Dec 31 2023	US$2m	US$750k	-US$84m
Sep 30 2023	n/a	n/a	US$10m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$135m
Dec 31 2022	US$5m	US$750k	-US$130m
Sep 30 2022	n/a	n/a	-US$132m
Jun 30 2022	n/a	n/a	-US$134m
Mar 31 2022	n/a	n/a	US$2m
Dec 31 2021	US$5m	US$724k	US$11m
Sep 30 2021	n/a	n/a	US$14m
Jun 30 2021	n/a	n/a	US$9m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$2m	US$1	US$91m
Sep 30 2020	n/a	n/a	US$62m
Jun 30 2020	n/a	n/a	-US$194m
Mar 31 2020	n/a	n/a	-US$199m
Dec 31 2019	US$446k	US$44k	-US$362m
Sep 30 2019	n/a	n/a	-US$339m
Jun 30 2019	n/a	n/a	-US$67m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$325k	n/a	-US$21m

Tazminat ve Piyasa: Chirag 'nin toplam tazminatı ($USD 2.37M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 6.79M ).

Tazminat ve Kazançlar: Chirag 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Chirag Patel (57 yo)

19.8yrs

Görev süresi

US$2,370,385

Tazminat

Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Chirag Patel	Co-Founder	19.8yrs	US$2.37m	7.04% $ 188.4m
Chintu Patel	Co-Founder	22.8yrs	US$2.37m	8.16% $ 218.5m
Anastasios Konidaris	Executive VP & CFO	4.6yrs	US$1.89m	0.17% $ 4.6m
Jason Daly	Senior VP	2.8yrs	US$1.35m	0.019% $ 495.9k
Nikita Shah	Executive VP & Chief Human Resources Officer	10.8yrs	US$1.53m	0.094% $ 2.5m
Andrew Boyer	Executive VP & Chief Commercial Officer of Generics	6.7yrs	US$1.94m	0.083% $ 2.2m
Anthony DiMeo	Head of Investor Relations	no data	Veri yok	Veri yok
Gregory Sgammato	Senior Vice President of Corporate Development	1.8yrs	Veri yok	Veri yok
Pranav Mehta	Senior VP of Strategic Sourcing & Supply Management	1.8yrs	Veri yok	Veri yok
Sanjay Jain	Chief Quality Officer	5.8yrs	Veri yok	Veri yok
Srinivas Kone	Senior VP & Chief Scientific Officer of Generics	4.8yrs	Veri yok	Veri yok
Stanley Fisher	Vice President & Head of Medical Affairs	no data	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: AMRX 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Chirag Patel	Co-Founder	19.8yrs	US$2.37m	7.04% $ 188.4m
Chintu Patel	Co-Founder	22.8yrs	US$2.37m	8.16% $ 218.5m
Paul Meister	Independent Chairman of the Board	5.2yrs	US$299.08k	0.24% $ 6.3m
J. Buchi	Independent Director	6.4yrs	US$302.20k	0.085% $ 2.3m
Ted Nark	Independent Director	6.4yrs	US$244.70k	0.097% $ 2.6m
Shlomo Yanai	Independent Director	4.8yrs	US$254.70k	0.079% $ 2.1m
Jeffrey George	Independent Director	4.8yrs	US$277.20k	0.087% $ 2.3m
Gautam Patel	Director	6.4yrs	US$217.20k	0.66% $ 17.7m
Deborah Autor	Independent Director	2.3yrs	US$267.04k	0.030% $ 807.8k
Emily Alva	Independent Director	6.4yrs	US$217.20k	0.081% $ 2.2m
John Kiely	Independent Director	4.8yrs	US$284.70k	0.083% $ 2.2m

6.4yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AMRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).

Amneal Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insider recently sold US$775k worth of stock

Insider notifies of intention to sell stock

Independent Director recently sold US$256k worth of stock

Independent Director notifies of intention to sell stock

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Insider exercised options and sold US$332k worth of stock

Recent updates

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold US$775k worth of stock

Insider notifies of intention to sell stock

Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant

Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies

Independent Director recently sold US$256k worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$8.25

New major risk - Negative shareholders equity

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Price target increased by 7.3% to US$7.31

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Insider exercised options and sold US$332k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 17%

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

New major risk - Financial position

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Price target increased by 50% to US$5.25

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals Could Have An Upbeat Q2

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Consensus EPS estimates fall by 25%

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

Price target decreased by 18% to US$3.50

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Price target decreased by 18% to US$4.20

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Amneal Pharmaceuticals: Risk Still Persists

Amneal Pharma reaffirms 2022 guidance

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Amneal Pharmaceuticals large shareholder TPG cuts stake

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Price target decreased to US$5.10

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Third quarter 2022 earnings: EPS and revenues miss analyst expectations